1740 / 1816
Cardiovascular toxicity – trastuzumab
• Trastuzumab is associated with cardiomyopathy
• Assesment of LVEF is indicated
• Data combination trastuzumab and radiotherapy
• NCCTG N9831 trial: No increased cardiotoxicity with concurrent
treatment
• Late effects are not known (FU 3.7 years)
• Concurrent trastuzumab with radiotherapy (with modern techniques,
cardiac sparing) may be continued
Perez, JCO 2011
19-9-2017